January 10, 2026 Acuitas Therapeutics Buys Majority Stake In RNA Technologies & Therapeutics Read about Acuitas Therapeutics Buys Majority Stake In RNA Technologies & Therapeutics
January 8, 2026 Acuitas Takes Majority stake in Montreal-based RNA Construct Manufacturer Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics. Read about Acuitas Takes Majority stake in Montreal-based RNA Construct Manufacturer
January 7, 2026 Acuitas Therapeutics: Interview With President & CEO Dr. Thomas Madden About The Biotech Company Read about Acuitas Therapeutics: Interview With President & CEO Dr. Thomas Madden About The Biotech Company
December 23, 2025 A Year of Firsts: Personalized Gene Editing Comes of Age Read about A Year of Firsts: Personalized Gene Editing Comes of Age
December 23, 2025 Seven Biopharma Trends to Watch in 2026 Read about Seven Biopharma Trends to Watch in 2026
December 15, 2025 A Look Ahead: Predictions for the Life Sciences in 2026 Read about A Look Ahead: Predictions for the Life Sciences in 2026
December 4, 2025 GEN Editors Reflect on Six of the Biggest Stories of the Year Alex Philippidis Read about GEN Editors Reflect on Six of the Biggest Stories of the Year
December 2, 2025 New and notable treatments from 2025 Read about New and notable treatments from 2025
December 1, 2025 From One Patient to Many: How Baby KJ is Ushering in a New Era in CRISPR Medicine Read about From One Patient to Many: How Baby KJ is Ushering in a New Era in CRISPR Medicine
October 16, 2025 Baby KJ’s doctors will ask FDA this winter to OK a clinical trial of pioneering gene editing approach Squirming toddler with a rare liver disease leaves barely a dry eye at STAT Summit Read about Baby KJ’s doctors will ask FDA this winter to OK a clinical trial of pioneering gene editing approach
